Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Fosgemcitabine Palabenamide · NUC-1031, BIO-1031

Small molecule · Inhibitor of ribonucleotide reductase

Phase 3 Most advanced trial (none active)
2 Registered trials

What is Fosgemcitabine Palabenamide?

Fosgemcitabine palabenamide is a phosphoramidate prodrug of gemcitabine that is converted inside cells into difluorodeoxycytidine diphosphate and triphosphate. The diphosphate inhibits ribonucleotide reductase, while the triphosphate is incorporated into DNA, terminating DNA replication and inducing apoptosis. It is studied in ovarian cancer and biliary tract cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
NUC-1031, BIO-1031, CPF-31
Drug type
Small molecule
Targets
ribonucleotide reductase
Mechanism
Inhibitor of ribonucleotide reductase
Pathways
DNA replication, apoptosis
Therapy area
Oncology
In trials of
NCNA
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3
UNII
I17GWP65CE

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT04163900 Phase 3 Biliary Tract Cancer Terminated NCNA
NCT03146663 Phase 2 Ovarian Cancer Terminated NCNA

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Biliary Tract CancerOvarian Cancer

Sources

Updated Oct 25, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.